NextCell invited to speak at Advance Therapies Congress in London
NextCell Pharma AB (“NextCell”) present the ongoing clinical trial program with the lead cell therapy drug candidate, ProTrans, at the Advanced Therapies Congress in London on May 24[th]-25[th]. The presentation will be given by NextCell’s CEO, Dr. Mathias Svahn on Wednesday.The first patient was treated with ProTrans in January 2018 and there are presently 4 clinical trials and one follow-up study ongoing. The active pharmaceutical ingredient in ProTrans is mesenchymal stromal cells from umbilical cord tissue. The patent pending selection algorithm is utilized for selection of cells and